Arch Biopartners’ cilastatin enters Phase II trial for AKI prevention
The Universities of Calgary and Alberta-based clinical team received $1.5m funding from CIHR for the trial.
05 August 2024
05 August 2024
The Universities of Calgary and Alberta-based clinical team received $1.5m funding from CIHR for the trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.